Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021

• DOI: 10.1001/jamanetworkopen.2022.5018
• Publication Date: 2022-03-31T22:40:06Z
• Authors: Tyler N. A. Winke...; Nayanjot K. Rai; Peter J. Bodurtha; Alanna M. Chamber...; Malini DeSilva; Jessica Jeruzal; Steven G. Johnson; Anupam Kharbanda; Niall Klyn; Pamela J. Mink; Miriam Muscoplat; Stephen Waring; Yue Yu; Paul E. Drawz
• Keywords: Herd Immunity

COVID-19 vaccines are effective, but inequities in vaccine administration and waning immunity may limit effectiveness.To report statewide trends effectiveness Minnesota.This cohort study used data from the Minnesota Immunization Information Connection October 25, 2020, through 30, 2021 that were linked with electronic health record (EHR) systems collaborating as part of EHR Consortium (MNEHRC). Participants included individuals who seen at a participating system Minnesota.Individuals considered fully vaccinated second week after receipt dose BNT162b2 or mRNA-1273 single an Ad26.COV.2.S vaccine.A completed vaccination series breakthrough, defined either positive SARS-CoV-2 polymerase chain reaction (PCR) test hospital admission same within 3 weeks following PCR test. A test-negative design incident rate ratio to evaluate separately for BNT162b2, mRNA-1273, vaccines. Rurality social vulnerability index assessed area level.This 4 431 190 unique systems, 013 704 (68%) vaccinated. Vaccination rates lowest among Minnesotans identified Hispanic (116 422 217 019 [54%]), multiracial (30 066 57 412 [52%]), American Indian Alaska Native (22 41 437 Black African (158 860 326 595 [49%]) compared Asian Pacific Islander (159 999 210 994 [76%]) White (2 402 928 391 747 [71%]). Among aged 19 64 years, lower rural areas (196 479 308 047 [64%]) urban (151 541 1 951 265 [77%]) high (544 433 774 952 [70%]) low (571 613 724 369 [79%]). In 9 ending 2021, by was 33% (95% CI, 30%-37%) Ad26.COV.2.S; 53% 52%-54%) BNT162b2; 66% 65%-67%) mRNA-1273. For SARS-CoV-2-related hospitalizations, 78% 75%-81%) 81% 79%-82%) mRNA-1273.This consortium suggests disparities effectiveness. Vaccine against infection associated protection hospitalizations despite increased prevalence Delta variant Minnesota.